These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 11703570)

  • 21. Alpha interferon inhibits hepatitis C virus replication in primary human hepatocytes infected in vitro.
    Castet V; Fournier C; Soulier A; Brillet R; Coste J; Larrey D; Dhumeaux D; Maurel P; Pawlotsky JM
    J Virol; 2002 Aug; 76(16):8189-99. PubMed ID: 12134024
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synergistic inhibition of intracellular hepatitis C virus replication by combination of ribavirin and interferon- alpha.
    Tanabe Y; Sakamoto N; Enomoto N; Kurosaki M; Ueda E; Maekawa S; Yamashiro T; Nakagawa M; Chen CH; Kanazawa N; Kakinuma S; Watanabe M
    J Infect Dis; 2004 Apr; 189(7):1129-39. PubMed ID: 15031779
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics.
    Marcello T; Grakoui A; Barba-Spaeth G; Machlin ES; Kotenko SV; MacDonald MR; Rice CM
    Gastroenterology; 2006 Dec; 131(6):1887-98. PubMed ID: 17087946
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Very early viral kinetics on interferon treatment in chronic hepatitis C virus genotype 4 infection.
    Jessner W; Gschwantler M; Formann E; Gurguta C; Watkins-Riedel T; Wrba F; Ferenci P
    Antivir Ther; 2008; 13(4):581-9. PubMed ID: 18672537
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study.
    Farrell GC; Bacon BR; Goldin RD
    Hepatology; 1998 Apr; 27(4):1121-7. PubMed ID: 9537453
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Selection of genetic variants of the 5' noncoding region of hepatitis C virus occurs only in patients responding to interferon alpha therapy.
    Lu M; Wiese M; Roggendorf M
    J Med Virol; 1999 Oct; 59(2):146-53. PubMed ID: 10459148
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hammerhead ribozymes with cleavage site specificity for NUH and NCH display significant anti-hepatitis C viral effect in vitro and in recombinant HepG2 and CCL13 cells.
    Gonzalez-Carmona MA; Schüssler S; Serwe M; Alt M; Ludwig J; Sproat BS; Steigerwald R; Hoffmann P; Quasdorff M; Schildgen O; Caselmann WH
    J Hepatol; 2006 Jun; 44(6):1017-25. PubMed ID: 16469406
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mizoribine inhibits hepatitis C virus RNA replication: effect of combination with interferon-alpha.
    Naka K; Ikeda M; Abe K; Dansako H; Kato N
    Biochem Biophys Res Commun; 2005 May; 330(3):871-9. PubMed ID: 15809077
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hairpin ribozymes in combination with siRNAs against highly conserved hepatitis C virus sequence inhibit RNA replication and protein translation from hepatitis C virus subgenomic replicons.
    Jarczak D; Korf M; Beger C; Manns MP; Krüger M
    FEBS J; 2005 Nov; 272(22):5910-22. PubMed ID: 16279954
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interferon alfacon-1 and ribavirin versus interferon alpha-2b and ribavirin in the treatment of chronic hepatitis C.
    Sjogren MH; Sjogren R; Holtzmuller K; Winston B; Butterfield B; Drake S; Watts A; Howard R; Smith M
    Dig Dis Sci; 2005 Apr; 50(4):727-32. PubMed ID: 15844709
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Continuous interferon-α2b infusion in combination with ribavirin for chronic hepatitis C in treatment-experienced patients.
    Roomer R; Bergmann JF; Boonstra A; Hansen BE; Haagmans BL; Kwadijk-de Gijsel S; van Vuuren AJ; de Knegt RJ; Janssen HL
    Antivir Ther; 2012; 17(3):509-17. PubMed ID: 22300892
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group.
    Tong MJ; Reddy KR; Lee WM; Pockros PJ; Hoefs JC; Keeffe EB; Hollinger FB; Hathcote EJ; White H; Foust RT; Jensen DM; Krawitt EL; Fromm H; Black M; Blatt LM; Klein M; Lubina J
    Hepatology; 1997 Sep; 26(3):747-54. PubMed ID: 9303508
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 9-cis retinoic acid enhances the antiviral effect of interferon on hepatitis C virus replication through increased expression of type I interferon receptor.
    Hamamoto S; Fukuda R; Ishimura N; Rumi MA; Kazumori H; Uchida Y; Kadowaki Y; Ishihara S; Kinoshita Y
    J Lab Clin Med; 2003 Jan; 141(1):58-66. PubMed ID: 12518169
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antiviral action of interferon-alpha against hepatitis C virus replicon and its modulation by interferon-gamma and interleukin-8.
    Jia Y; Wei L; Jiang D; Wang J; Cong X; Fei R
    J Gastroenterol Hepatol; 2007 Aug; 22(8):1278-85. PubMed ID: 17565587
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An early viral response to standard interferon-alpha identifies resistance to combination therapy with peginterferon and ribavirin in patients infected by HCV genotype 1.
    Toyoda H; Kumada T; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Tada T; Takagi M; Hiramatsu T; Hosokawa T; Arakawa T; Fujimori M
    J Med Virol; 2010 Sep; 82(9):1537-44. PubMed ID: 20648607
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A multicenter, randomized, controlled trial of interferon alfacon-1 compared with alpha-2a-interferon in Chinese patients with chronic hepatitis C virus infection.
    Yao GB; Fu XX; Tian GS; Xu DZ; Hao LJ; Huangfu YS; Su CX
    J Gastroenterol Hepatol; 2000 Oct; 15(10):1165-70. PubMed ID: 11106097
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quantification of serum hepatitis C virus RNA with daily or standard interferon doses plus ribavirin in nonresponder patients with chronic hepatitis C.
    Buti M; Olive G; Stalgis C; Esteban R; Guardi J
    Dig Dis Sci; 2000 Apr; 45(4):685-9. PubMed ID: 10759235
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro inhibition of the hepatitis delta virus replication mediated by interferon and trans-ribozyme or antisense probes.
    Madejón A; Bartolomé J; Carreño V
    J Hepatol; 1998 Sep; 29(3):385-93. PubMed ID: 9764984
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term pegylated interferon monotherapy following 72 weeks of pegylated interferon and ribavirin in hepatitis C virus genotype-1-infected slow responders.
    Watanabe S; Kobayashi Y; Kawata K; Noritake H; Chida T; Nagasawa M; Kageyama F; Kawamura K; Sasada Y; Suda T
    Intern Med; 2015; 54(3):273-9. PubMed ID: 25748735
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Influence of miR-122 on IFN-α treatment for HCV infection].
    Li SJ; Chen Z; Zhu HH
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2011 Nov; 40(6):588-92, 652. PubMed ID: 22190517
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.